Results 281 to 290 of about 198,039 (308)

Immune Checkpoint Inhibitor Therapy in Hormone Receptor-Positive Breast Cancer. [PDF]

Int J Mol Sci
Lin D, Bitar JSL, Ma I, Yuan Y.
europepmc   +1 more source

Immune-modulating medications: the masquerading culprit of epididymo-orchitis. [PDF]

BMJ Case Rep
Buchinsky DS, Polenakovik HM, Hakim JI.
europepmc   +1 more source

Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC: Real-world evidence

Irina Surovtsova, Felix Herth, Daria B. Kokh, Philipp Morakis   +3 more
openalex   +1 more source

Selecting optimal immunotherapy based on inflammation in stage IV PD-L1 ≥50% gene mutation-negative non-small cell lung cancer: pembrolizumab monotherapy versus combination chemoimmunotherapy. [PDF]

Transl Lung Cancer Res
Kunimatsu Y, Nishioka N, Yamada T, Kawachi H, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Ishida M, Kijima T, Takayama K.   +19 more
europepmc   +1 more source

A new strategy for melanoma treatment: an investigation of the clinical value of the combination of immune checkpoint inhibitors and oncolytic viruses. [PDF]

Cancer Cell Int
Sui B, Jin X, Zheng X.
europepmc   +1 more source

Subcutaneous administration of pembrolizumab: a paradigm shift toward patient-centered cancer care. [PDF]

J Thorac Dis
Kobayashi N.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Immunotherapies for hepatocellular carcinoma

Nature Reviews Clinical Oncology, 2021
, Florian Castet, Mala K Maini
exaly  

Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort

Nature Medicine, 2022
Antoine Italiano, Emmanuelle Bompas, Catherine Sautes-fridman   +2 more
exaly